ADC Therapeutics Management
Management criteria checks 3/4
ADC Therapeutics' CEO is Ameet Mallik, appointed in May 2022, has a tenure of 2.67 years. total yearly compensation is $3.78M, comprised of 19.1% salary and 80.9% bonuses, including company stock and options. directly owns 0.96% of the company’s shares, worth $1.70M. The average tenure of the management team and the board of directors is 2.2 years and 4.2 years respectively.
Key information
Ameet Mallik
Chief executive officer
US$3.8m
Total compensation
| CEO salary percentage | 19.1% |
| CEO tenure | 2.7yrs |
| CEO ownership | 1.0% |
| Management average tenure | 2.2yrs |
| Board average tenure | 4.2yrs |
Recent management updates
Recent updates
ADC Therapeutics: Continues To Make Strides With ZYNLONTA Targeting DLBCL
Dec 12Investors Don't See Light At End Of ADC Therapeutics SA's (NYSE:ADCT) Tunnel And Push Stock Down 26%
Nov 16
ADC Therapeutics SA (NYSE:ADCT) Surges 34% Yet Its Low P/S Is No Reason For Excitement
Jul 18Limiting Concerns On ADC Therapeutics' Prospects
Jun 06ADC Therapeutics SA's (NYSE:ADCT) 26% Dip In Price Shows Sentiment Is Matching Revenues
May 30Analysts Are Updating Their ADC Therapeutics SA (NYSE:ADCT) Estimates After Its First-Quarter Results
May 10ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade)
Mar 19ADC Therapeutics SA's (NYSE:ADCT) 29% Dip In Price Shows Sentiment Is Matching Revenues
Mar 17ADC Therapeutics SA (NYSE:ADCT) Shares Fly 38% But Investors Aren't Buying For Growth
Jan 18ADC Therapeutics: Rising From The Ashes Of A Halted Drug Trial
Dec 29An Intrinsic Calculation For ADC Therapeutics SA (NYSE:ADCT) Suggests It's 38% Undervalued
Dec 14ADC Therapeutics: Navigating A Swirling Drain
Dec 01ADC Therapeutics: Slowly Moving Toward Solvency
Aug 29Are Investors Undervaluing ADC Therapeutics SA (NYSE:ADCT) By 32%?
Jul 11ADC Therapeutics: Maybe A 2024 Story
May 29Analysts Have Just Cut Their ADC Therapeutics SA (NYSE:ADCT) Revenue Estimates By 28%
May 11ADC Therapeutics SA's (NYSE:ADCT) Shares Lagging The Industry But So Is The Business
Apr 18ADC Therapeutics stock slips after pricing stock offering by seller
Feb 02Does ADC Therapeutics (NYSE:ADCT) Have A Healthy Balance Sheet?
Jan 16Jose Carmona joins ADC Therapeutics as CFO
Dec 19ADC Therapeutics Non-GAAP EPS of $0.13, revenue of $76.32M
Nov 08ADC, Sobi Zynlonta for blood cancer subtype gets EMA panel backing for EU approval
Sep 16ADC Therapeutics gets downgraded at Morgan Stanley, price target cut to $11
Sep 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$212m |
| Jun 30 2024 | n/a | n/a | -US$215m |
| Mar 31 2024 | n/a | n/a | -US$227m |
| Dec 31 2023 | US$4m | US$721k | -US$240m |
| Sep 30 2023 | n/a | n/a | -US$181m |
| Jun 30 2023 | n/a | n/a | -US$184m |
| Mar 31 2023 | n/a | n/a | -US$200m |
| Dec 31 2022 | US$11m | US$475k | -US$157m |
Compensation vs Market: Ameet's total compensation ($USD3.78M) is above average for companies of similar size in the US market ($USD1.42M).
Compensation vs Earnings: Ameet's compensation has been consistent with company performance over the past year.
CEO
Ameet Mallik (51 yo)
2.7yrs
Tenure
US$3,779,425
Compensation
Dr. Ameet Mallik M.B.A., M.S, is Director at ADC Therapeutics SA from June 30, 2022. He has been a Director of Atara Biotherapeutics, Inc. since August 2021. Dr. Mallik serves as Chief Executive Officer at...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.7yrs | US$3.78m | 0.96% $ 1.7m | |
| Chief Financial Officer | 2.1yrs | US$1.26m | 0.31% $ 552.5k | |
| Chief Medical Officer | 2yrs | US$4.40m | 0.24% $ 426.2k | |
| Corporate Controller & Chief Accounting Officer | no data | no data | 0.037% $ 65.9k | |
| Chief Technical Officer | 1yr | no data | no data | |
| Chief Scientific Officer | 3yrs | no data | no data | |
| Investor Relations Officer | no data | no data | no data | |
| Secretary & Chief Legal Officer | 2.2yrs | no data | 0.20% $ 345.0k | |
| Vice President of Investor Relations & Corporate Communications | no data | no data | no data | |
| Senior VP & Chief People Officer | 4.4yrs | no data | no data | |
| Chief Commercial Officer | 2.2yrs | no data | no data |
2.2yrs
Average Tenure
55yo
Average Age
Experienced Management: ADCT's management team is considered experienced (2.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.6yrs | US$3.78m | 0.96% $ 1.7m | |
| Board Observer | 1.6yrs | US$846.56k | no data | |
| Vice-Chairman & Lead Independent Director | 5.6yrs | US$212.61k | 0.15% $ 261.0k | |
| Chairman of the Board | 4.8yrs | US$526.73k | 1.6% $ 2.8m | |
| Independent Non-Executive Director | 2.6yrs | US$197.81k | 0.059% $ 104.1k | |
| Independent Non-Executive Director | 6.6yrs | no data | no data | |
| Independent Non-Executive Director | 4.8yrs | US$227.72k | 0.074% $ 131.8k | |
| Independent Director | 1.6yrs | US$127.67k | 0.024% $ 42.7k | |
| Independent Non-Executive Director | 3.6yrs | US$231.33k | 0.098% $ 173.5k | |
| Non-Independent Director | 8.3yrs | US$194.30k | 0.18% $ 318.2k |
4.2yrs
Average Tenure
57.5yo
Average Age
Experienced Board: ADCT's board of directors are considered experienced (4.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/21 23:31 |
| End of Day Share Price | 2025/01/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ADC Therapeutics SA is covered by 19 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Lut Ming Cheng | Cantor Fitzgerald & Co. |
| Eric Schmidt | Cantor Fitzgerald & Co. |